Skyhawk Therapeutics has made significant progress with its innovative drug candidate, SKY-0515, which is engineered to be an RNA splicing modifier.

Tonix Pharmaceuticals Holding Corp. has finished the clinical phase of its Phase 1 trial for TNX-1500, a humanized monoclonal antibody (mAb) designed to prevent organ transplant rejection and treat autoimmune diseases.

PharmAust Limited has reported that its drug monepantel (MPL) has outperformed the FDA-approved Relyvrio® in terms of safety and tolerability.

S.BIOMEDICS Co., Ltd., a leading company in stem cell therapy, has recently completed a Phase 1/2a clinical trial involving the transplantation of TED-A9 cells into the brains of 12 Parkinson's disease patients.

This research is centered on RGX-202, an experimental treatment for Duchenne muscular dystrophy.

NeuroBo Pharmaceuticals announced that it has received IRB approval for its Phase 1 clinical trial of DA-1726, targeting obesity.

Innovent Biologics has initiated a phase 1 clinical trial for IBI3002 in Australia.

Kiromic BioPharma has announced the successful completion of treatment by the third participant in its Phase 1 Deltacel-01 clinical trial.

ELLAS Life Sciences Group has reported significant findings from their Phase 1 clinical trial of SLS009, a CDK9 inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).

FogPharma recently announced securing $145 million in a Series E funding round aimed at advancing its solid tumor treatment into clinical trials.

Neurogene Inc. is advancing its Phase 1/2 clinical trial for NGN-401, a gene therapy for Rett syndrome in female pediatric patients.

Molecular Templates highlighted the promising results of their monotherapy drug candidate, MT-6402, particularly in patients with head and neck cancer.